A73 Abstracts (US/UK). Patients also provided their opinions of current CT with DFO to ensure that no major concepts were omitted. RESULTS: The literature review revealed no IO or CT specific questionnaires, though several articles recounted DFO's inconvenience and impact. Patient and clinician interviews suggested that patients were most concerned about the efficacy, side effects, convenience and costs of any new IO treatment. Satisfaction with DFO was low, primarily due to local site reactions, inconvenience, and the constraining nature of the therapies. Presented with a hypothetical oral CT, patients unanimously preferred oral CT. A 40-item questionnaire was developed that assessed patients' expectations of and satisfaction with attributes identified as important including efficacy, safety, convenience and side effects, along with costs, overall satisfaction, treatment impact, patient compliance, and preferences. Results from the content validity testing resulted in additions to the instructions and the rewording of six items. CONCLUSIONS: To accurately assess satisfaction, patient input should be obtained. In the absence of real-life experience with the proposed therapy, unbiased hypothetical product profiles were used to elicit the dimensions important to patients, and this is consistent with established methods. Psychometric validation is currently underway.
PMC28 ITEM RESPONSE BIAS IN INSTRUMENTAL ACTIVITY DAILY LIVING SCALE IN ASIAN OLDER ADULTS
Niti M 1 , Ng TP 1 , Chiam PC 2 , Kua EH 1 1 National University of Singapore, Singapore, Singapore, Singapore; 2 Institute of Mental Health, Singapore, Singapore, Singapore OBJECTIVE: Item response bias (also called differential item functioning, DIF) in Instrumental Activities of Daily Living (IADL) occurs when members of different groups possessing the same disability level do not have the same probability of responding positively for a given item(s). This study aimed to identify the extent of DIF by gender, age, ethnicity and dementia groups in IADL estimates in Asian (Chinese, Malay and Indian) elderly subjects. METHODS: Data of the 2003 National Mental Health Survey were analyzed from 1072 non-institutionalized elderly subjects using multiple indicator-multiple cause latent variable (MIMIC) modeling. RESULTS: Given the same functional level, older elderly were less likely to report receiving help with preparing meals; men were more likely to report receiving help with preparing meals, doing laundry, and taking medication; Malays were more likely to report receiving help with using telephone; and demented elderly were more likely to report receiving help with using telephone, managing money, taking medications, and "getting around". The impact of DIF on group differences was highest for gender (54.0%), ethnicity (42.9%), dementia (14.7%) and age (2.4%). CONCLU-SION: Item-response bias in IADL estimates by gender, age, ethnicity and dementia should be considered in direct comparisons of disability status among population groups.
MUSCULAR-SKELETAL DISORDERS PMD1 COST ANALYSIS OF MANAGEMENT STRATEGIES FOR CLOSED AND OPEN GRADE I TIBIAL SHAFT FRACTURES
Busse JW 1 , Bhandari M 1 , Sprague S 1 , Johnson-Masotti AP 2 , Gafni A 2 1 Hamilton General Hospital, Hamilton, ON, Canada; 2 McMaster University, Hamilton, ON, Canada OBJECTIVES: To conduct a cost analysis of current competing strategies for the management of patients with closed and open grade I tibial shaft fractures, from both a governmental and societal perspective. METHODS: Our cost analysis was performed for four competing treatment strategies for management of closed or grade I open tibial fractures: 1). casting alone; 2). casting with therapeutic ultrasound; 3). operative treatment with non-reamed intramedullary nailing; and 4). operative treatment with reamed intramedullary nailing. The time to radiographic fracture union was used as the measure of effectiveness. Given the multiple clinical alternatives, each with the potential to result in a number of outcomes, a decision tree was used to perform all cost analyses. Sensitivity analysis was conducted through Monte Carlo simulations. RESULTS: From a governmental perspective the mean associated costs were USD $3365 (standard deviation [SD] ± 1425) for operative management by reamed intramedullary nailing, $5041 (SD ± 1363) for operative management by non-reamed intramedullary nailing, $5017 (SD ± 1370) for casting, and $5312 (SD ± 1474) for casting with therapeutic ultrasound. From a societal perspective the mean associated costs were ($12,449; SD ± 4894) for reamed intramedullary nailing, ($13,266; SD ± 3692) for casting with therapeutic ultrasound, ($15,571; SD ± 4293) for operative management by non-reamed intramedullary nailing, and ($17,343; SD ± 4784) for casting alone. CONCLUSIONS: Our preliminary cost analysis suggests that, from both a governmental and societal perspective, reamed intramedullary nailing is the treatment of choice for closed and open grade I tibial shaft fractures. However, there is evidence that, from a societal perspective, treatment of low energy tibial fractures with therapeutic ultrasound and casting may also be an economically-sound intervention.
PMD2

COST-EFFECTIVENESS ANALYSIS OF ACLASTA IN PAGET'S DISEASE OF BONE IN BELGIUM
Lecomte P 1 , Devogelaer JP 2 , Kaufman JM 3 , Goemaere S 3 , Geusens P 4 , Engbersen A 5 1 Novartis Pharma, Vilvoorde, Belgium; 2 Cliniques UCL Saint-Luc, Brussels, Belgium; 3 Ghent University Hospital, Gent, Belgium; 4 Universiteit Hasselt, Diepenbeek, Belgium; 5 Novartis Pharma AG, Basel, Switzerland OBJECTIVES: To assess, in the Belgian setting, the costs, efficacy, and cost-effectiveness of zoledronic acid 5 mg (Aclasta) versus conventional therapies (tiludronate (Skelid), pamidronate (Aredia), and risedronate (Actonel)) in the management of patients with Paget's disease of bone (PDB). METHODS: Based on efficacy data from pivotal zoledronic acid 5 mg clinical trials and the literature, a decision tree model was developed to reflect the treatment path with the different drugs compared. This model takes into account four health states and links efficacy data to Belgian resource use data. It covers a 2-year time horizon. The outcome measure chosen is time in response, defined as time in which serum alkaline phosphatase is controlled. Direct medical costs, from the perspective of the health care payer (INAMI/RIZIV) were considered and discounting was applied in the second year. The consumption of medical resources (drug treatments including administration costs, laboratory tests, and physician consultations) was assessed via expert opinion. RESULTS: Over two years, the expected average numbers of months in response for patients treated with zoledronic acid 5 mg and conventional treatments (tiludronate, pamidronate, and risedronate) are: 20.9 months; 11.1 months; 9.3 months; and 16.2 months, respectively. Over this period, the expected average costs for patients treated with zoledronic acid 5 mg and conventional treatments (tiludronate, pamidronate, and risedronate) are: €686; €1525; €1245; and €793, respectively. Hence, zoledronic acid 5 mg dominates all the other bisphosphonates compared, i.e. zoledronic acid 5 mg is less costly and more effective.
